Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition - Lyrarakis, Georgios; Liontos, Michael; Anastasopoulou, Amalia; Bouros, Spyridon; Gkoufa, Aikaterini; Diamantopoulos, Panagiotis; Gogas, Helen; Ziogas, Dimitrios C. (Frontiers in Oncology, 2024)